Tracking What Enters the Market and What the Data Tell Us

FDA market authorization decisions provide one of the clearest views into the changing medical product landscape. Individually, each clearance or approval represents a regulatory decision. Viewed together and over time, they can reveal important patterns in technology, therapeutic areas, regulatory pathways, companies, and the products reaching the U.S. market.

MDP Market Authorization Intelligence tracks and analyzes these decisions to help identify where regulatory activity is occurring, how it is changing, and what those changes may mean for regulated industries.

Medical Device Authorizations

510(k) Premarket Notifications

The 510(k) pathway accounts for much of FDA’s medical device authorization activity. MDP analyzes clearance activity across submission types, product codes, regulatory specialties, applicants, countries, review timelines, and emerging technologies, with historical comparisons that help put current activity into context.

De Novo Authorizations

The De Novo pathway provides a route to market for novel low- to moderate-risk devices without an existing legally marketed predicate. Because De Novo authorization establishes a new device classification and may create a predicate for future 510(k)s, these decisions provide an important window into emerging technologies and new regulatory categories.

Premarket Approval (PMA)

PMA is FDA’s most stringent medical device premarket pathway and generally applies to high-risk Class III devices. MDP distinguishes original PMA approvals from PMA supplements, allowing us to examine both new products and the continuing evolution of existing technologies through changes to design, manufacturing, software, labeling, indications, and other aspects of the product lifecycle.

Drugs & Biologics

MDP also monitors significant drug and biologic approvals and the regulatory programs that influence their development and review. This includes conventional approvals as well as activity involving programs such as Priority Review, Fast Track, Breakthrough Therapy, Accelerated Approval, RMAT, and Orphan Drug designation.

From Regulatory Data to Regulatory Intelligence

A monthly authorization total tells us what happened. Historical analysis helps tell us whether it matters.

We utilize current and longitudinal regulatory data to examine monthly activity, year-over-year changes, review patterns, five- and ten-year trends, emerging technologies, industry activity, and longer-term changes in the FDA authorization landscape.

As the program grows, this page will connect to monthly reports, historical analyses, data visualizations, notable authorizations, and other market authorization research.

The authorization is the regulatory event. Intelligence comes from understanding what it tells us.